Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE) (MY-CHOICE)

28 de abril de 2026 atualizado por: University of Southern Denmark

Online Personalized and Patient-preferred Comprehensive Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)

The goal of this feasibility study is to assess if the personalised online psychological intervention MY-CHOICE is acceptable to adults with ischemic heart disease and anxiety or depression. It will also examine the reasons for drop-out. The main questions the study aims to answer are:

How many participants complete the intervention and what are the reasons for drop-out. And what are the pre-post change scores on anxiety and depression.

Participants will:

Complete the MY-CHOICE intervention consisting of 6-12 weeks with online modules on various topics based on individual needs in combination with video- or telephone calls with a therapist (psychologist or a trained master student in Psychology) on a need-to basis.

Answer a set of questionnaires pre and post intervention. Participate in a brief interview post intervention.

Visão geral do estudo

Status

Recrutamento

Intervenção / Tratamento

Descrição detalhada

The MY-CHOICE project will assess the feasibility of a therapist-assisted eHealth intervention on patient satisfaction and dropout (barriers and facilitators), quality of life, and procedures with respect to recruitment and implementation in the CR settings. It is hypothesized that a therapist-assisted eHealth intervention that is personalized to patients' needs and preferences and that allows patients to engage in the intervention when and where they want, may reduce patients' barriers for seeking and engaging in treatment (e.g. drop-out).

Study design The MY-CHOICE intervention is a new comprehensive eHealth program for patients with IHD based on the premise of personalized medicine.

The intervention targets depression, anxiety and other common challenges met by patients with IHD attending CR that have been shown to impact on patients' quality of life, prognosis, motivation for self-care, compliance, and risk factor management.

Using a pre- post-test design, the study will examine the feasibility of (i) the intervention in 30 patients with IHD and co-morbid depression and/or anxiety referred to CR at one of the participating sites, including asking patients about the reason for drop-out at the time of drop-out, and (ii) evaluate the procedures for recruitment at the participating CR sites with respect to conducting a potential RCT and future implementation in routine care. Post intervention, investigators will ask all patients and 3-6 members of the CR team to complete a set of questions online related to identify barriers and facilitators for implementing the intervention in clinical care at a patient and organizational level.

Study population Patients will be recruited from cardiac rehabilitation centers in Denmark.

Study aims The primary aim of the study is to explore how patients experience and react to the intervention. We assess patients´ adherence, drop-out rate and treatment satisfaction.

The secondary aim is to assess the limited efficacy measured as the change in score on anxiety and depression (HADS) from baseline to 3-month follow-up.

MY-CHOICE intervention The intervention will partly be built on the principles of Cognitive Behavioral Therapy but also include core elements from several other psychological therapies like Acceptance and Commitment Therapy, Compassion Focused Therapy, existential psychology and Metacognitive Therapy. All patients will receive 4 mandatory core treatment modules for depression and anxiety. However, as the intervention is flexibly targetable to the individual patient's needs and preferences, and also designed to include and retain socially vulnerable patients and patients at risk of drop out - patients will choose the other modules and topics that they want to work with in a dialogue with the therapist. A flexible treatment is preferred, because each patient's life and symptom composition are different. The rationale is that an intervention tailored towards the specific anxiety and depression symptoms experienced by the individual patient is thought to be more effective than a one-size-fits all intervention.

There is a total of 13 optional modules, and depending on the treatment duration, patients will have time to complete 3-8 optional modules. The choice of modules can be adapted during the intervention, as patients' needs may change over time. After reading a short description of the optional modules, patients will be asked to indicate their preferred modules. When patients have expressed their preferences, they will talk to their therapist, who will help them decide between the optional modules.

Patients will work through the different modules, guided and supported by a therapist through asynchronous text messages. Motivational interviewing will be an integral part of the intervention to prevent drop-out. Treatment progress will be monitored every week by means of symptom questionnaires (CORE-10) that patients complete online via the platform. This information will be used in a dialogue between patients and therapists to steer the intervention, with adaptations made, if the expected progress is not seen. Therapists may contact patients via telephone during the intervention if needed. In addition to the 17 psychological intervention modules (4 mandatory, 13 optional), there will be 3 optional modules, focused on physical health and risk factor management (i.e. exercise, diet, and smoking). These modules will be offered to patients if they need more help after completing a psychologically focused module about lifestyle changes. The therapist can refer the patient to our Health Coach (HC) who is a trained physiotherapist educated in smoking cessation and diet. The HC will assess what kind of help the patient needs (e.g. refer the patient to existing treatment in the municipalities or the CR setting), or if the patient needs more, they can be offered to complete one or several of the health modules. Like the therapists, the HC will communicate with the patients by video call/phone, or written messages on the treatment platform.

All patients will have access to the material of the intervention so that they can revisit and reuse it on a need-to basis until 4 weeks after the last patient has completed the intervention. The eHealth intervention will be delivered by psychologists and master level students in psychology all employed at SDU and specialized in online psychology. The online platform (Minddistrict.com), is GDPR compliant and users log in using two-factor-authentication.

As part of the intervention, patients will be asked to complete the CORE-10 questionnaire every week to evaluate the patient's progress. Item 6 considers frequency of suicidal plans and is used as a continuous measurement of the suicidal risk of the patient. Any score above 0 will result in preventive actions from the therapist.

Procedure Within 2 weeks after discharge for an acute event from the hospital, patients with IHD are referred to a 12-week CR program. As part of current clinical practice, patients are screened for symptoms of depression and anxiety with the HADS or with the WHO-5 + MDI-2 and ASS-2 depending on the standard procedures of the site. Given that there is often a time lag between hospital referral of the patient to CR and the time that the patient can start the CR program, study procedures ensure that patients referred with a positive screening still have a positive screening at the time of inclusion into the study. Staff at the participating sites will obtain written informed consent prior to inclusion. Patients who consent will receive the baseline questionnaire package online, including the HADS, and will be contacted by telephone by one of the therapists after completion. If the HADS is negative the patient will be excluded and if positive the therapist will 1) seek to exclude major psychopathology including high suicidal risk and 2) assess whether the patient is likely to adhere to- and benefit from the treatment based on motivation, available time and energy, writing/reading capabilities and IT literacy. The interview is a standardized telephone interview, partly based on the psychiatric interview Schedules of Clinical Assessment in Neuropsychiatry (SCAN). If the therapist concludes the patient is not eligible based on the previous two criteria the patient will be excluded. If eligible, the patient will be offered the intervention and receive an appointment for a telephone-based start interview with the assigned therapist. In the start interview patients' individual symptoms of anxiety and depression will be mapped by the therapist, who will suggest how MY-CHOICE could be tailored to the patients' individual symptoms and psychological needs.

Measures and data collected The participating centers will search the patients´ medical records to determine whether patients are eligible to participate based on the inclusion and exclusion criteria. To document in/exclusion criteria this information (i.e., severe psychiatric disorder (borderline disorder, schizophrenia or bipolar disorder) (y/n), severe cognitive difficulties (y/n)), will be registered in the project database REDCap along with the patients´ planned rehabilitation (physical training, patient education, diet, and/or smoking cessation) and medical treatment for IHD (Percutaneous coronary intervention, Coronary artery bypass surgery and/or medication) for description of the study population. If patients sign the informed consent form, or want time to consider participation, their CPR-number, name, and telephone number will be registered in the project database, to enable the research team and the therapists to contact the patients who have consented to participate and to send a link to the electronic consent form to patients with time to consider. Further information on patients' demographic and clinical characteristics will be captured from purpose-designed questions in the questionnaire. Information on patients' use of the platform (e.g. time spent on platform, exercises completed) will be obtained from logging on the GDPR secure platform. All patients will complete the questionnaires at baseline and 3-months' follow-up to (i) indicate priorities for patients to work on, and (ii) use as outcome measures (see Table 1).

Data analyses The analyses will focus on assessing the limited efficacy, drop-out, adherence, and acceptability of the intervention. Due to the exploratory nature of the feasibility study, a formal power analysis was not conducted, and the sample size was determined pragmatically.

To evaluate limited efficacy, changes from baseline to 3 months follow-up on HADS-A and HADS-D will be analyzed, focusing on mean change scores as well as the proportion of study participants achieving a change score of at least 2-points, thus exceeding the minimal clinically important difference (MCID) of the HADS (36). Change score analyses will also be conducted for the Perceived Stress Scale (PSS) and Heart QoL to examine pre- to post-intervention differences.

Drop-out rates and loss to follow-up will be evaluated and summarized as counts and proportions. Adherence will be evaluated based on participants´ engagement with the intervention. Patient satisfaction with the eHealth intervention will be assessed using the 6-item Internet evaluation and usability questionnaire. To further examine acceptability, purpose-designed, qualitative open-ended questions evaluating the intervention will be collected at 3-month follow-up and explored using content analysis to identify key themes related to patients' experiences. Additionally, 6-10 patients will be interviewed post-intervention to add in-depth information about patients´ experiences with the intervention. Interviews will be transcribed and analyzed using Template Analysis.

Results from the quantitative measures will be presented descriptively, using means, standard deviations, ranges, frequencies, and proportions as appropriate.

The statistical analyses will be carried out using R statistical software.

Tipo de estudo

Intervencional

Inscrição (Estimado)

30

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aalborg, Dinamarca, 9000
        • Recrutamento
        • Aalborg University Hospital, Department of Cardiology
        • Contato:
          • Pia Behrndtz, Head nurse
          • Número de telefone: +45 21 53 13 49
          • E-mail: pib@rn.dk
        • Investigador principal:
          • Bent Raungaard, MD
      • Aarhus, Dinamarca, 8200
        • Recrutamento
        • Aarhus University Hospital, Department of Cardiology
        • Contato:
        • Investigador principal:
          • Helle L Kanstrup, MD
      • Roskilde, Dinamarca, 4000
        • Recrutamento
        • Zealand University Hospital, Roskilde, Department of Cardiology
        • Contato:
        • Investigador principal:
          • Kirsten Charlotte Helmark, PhD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • ischemic heart disease (diagnostic codes I20-I25),
  • referred for CR with a positive screen for depression and/or anxiety with the Hospital Anxiety and Depression Scale (HADS ≥ 8)
  • access to and ability to use a computer or tablet
  • proficient in the Danish language

Exclusion Criteria:

  • Severe psychiatric disorder (i.e., borderline disorder, schizophrenia or bipolar disorder) that requires psychiatric care
  • severe cognitive difficulties (e.g., severe brain damage, mental retardation, or dementia) that will prevent patients from participating
  • endorsement of suicidal ideation with suicidal thoughts (purpose designed questions) that cannot be handled in the intervention
  • participation in other intervention studies focused (unless they are clinical studies)
  • seeing a psychologist or mental health professional for the treatment of anxiety and depression
  • not being able or willing to spend 3-4 hours on the intervention each week
  • experiencing significant life stressors that hinder adherence to the MY-CHOICE treatment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Psychological intervention

Online psychological intervention for anxiety and depression, tailored to the patients´ individual needs. Duration 6-12 weeks.

The psychological intervention is provided as add-on to treatment as usual (i.e., the patients´ individual medical treatment and rehabilitation program.)

Online psychological treatment of anxiety and depression for patients with ischemic heart disease tailored to individual needs. The treatment includes access to an online treatment platform offering psychological content and written communication with the therapist and telephone-video conversations with the therapist. The intervention is tailored to meet the patients´ individual needs.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Drop-out rate
Prazo: From enrollment to end of treatment i.e., from 0 to 13 weeks
From enrollment to end of treatment i.e., from 0 to 13 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Limited efficacy on depression (HADS-D)
Prazo: From baseline to completion of 3-month follow-up which is administered after 13 weeks.
Limited efficacy: changes from baseline to 3 months follow-up on Hospital Anxiety and Depression Scale - Depression (HADS-D) will be analyzed, focusing on mean change scores as well as the proportion of study participants achieving a change score of at least 2-points in any direction. HADS-D have a score range of 0-21 with lower score indicating better outcome.
From baseline to completion of 3-month follow-up which is administered after 13 weeks.
Limited efficacy Anxiety (HADS-A)
Prazo: From completion of baseline questionnaire to completion of post intervention questionnaire administered 13 weeks after enrollment.
Limited efficacy: changes from baseline to 3 months follow-up on Hospital Anxiety and Depression Scale - Anxiety (HADS-A) will be analyzed, focusing on mean change scores as well as the proportion of study participants achieving a change score of at least 2-points. HADS-A have a score range of 0-21 with lower score indicating better outcome.
From completion of baseline questionnaire to completion of post intervention questionnaire administered 13 weeks after enrollment.
Patient satisfaction with intervention
Prazo: Administered in the FU-questionnaire 13 weeks after enrollment
Patient satisfaction with the eHealth intervention will be assessed using the 6-item Internet evaluation and usability questionnaire. (Range 0-24 and higher score indication higher satisfaction)
Administered in the FU-questionnaire 13 weeks after enrollment
adherence to intervention
Prazo: immediately after completion of intervention. i.e. between 6 and 12 weeks depending on the length of intervention. Possibly sooner if a patient drops out.
Adherence will be evaluated based on participants´ engagement with the intervention. Each intervention module assigned to the individual patient will be rated as either completed or not by the therapist based on patients' activity on the platform and information from the video-/phone therapy sessions.
immediately after completion of intervention. i.e. between 6 and 12 weeks depending on the length of intervention. Possibly sooner if a patient drops out.
Limited efficacy on stress
Prazo: Administered in the FU-questionnaire 13 weeks after enrollment
Change score analyses will be conducted for the Perceived Stress Scale (PSS) to examine pre- to post-intervention differences. The PSS has a range of 0-40 with a higher score indicating higher levels of perceived stress
Administered in the FU-questionnaire 13 weeks after enrollment
Limited efficacy on quality of life
Prazo: Administered in the FU-questionnaire 13 weeks after enrollment
Change score analyses will be conducted for Heart QoL to examine pre- to post-intervention differences. Heart QoL has a range of 0-42 with higher scores indication better outcome
Administered in the FU-questionnaire 13 weeks after enrollment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de julho de 2025

Conclusão Primária (Estimado)

1 de outubro de 2026

Conclusão do estudo (Estimado)

1 de outubro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

25 de março de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de abril de 2026

Primeira postagem (Real)

6 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de abril de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 12.414
  • S-20200112 (Outro identificador: the Regional Committees on Health Research Ethics for Southern Denmark)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Online psychological therapy

Se inscrever